Constipation on GLP-1 Drugs: Why It Happens and How to Manage It

Constipation is less discussed than nausea as a GLP-1 side effect, but it is comparably common and, for many patients, more persistent. While nausea typically front-loads at each dose step and improves, constipation can become a more chronic feature of GLP-1 therapy.

This article awaits medical-reviewer signoff.

Why GLP-1 drugs cause constipation

GLP-1 agonism slows gastric emptying — the rate at which the stomach empties into the small intestine. This same slowing effect extends throughout the gastrointestinal tract. Colonic transit time increases, meaning stool spends longer in the colon, which continues absorbing water from it. The result: stools become harder, less frequent, and more difficult to pass.

Why it behaves differently from nausea:

Nausea from GLP-1 therapy is largely mediated through central emetic centres (brainstem) that can adapt with receptor desensitisation over time. Colonic transit slowing is a more directly mechanical effect on gut motility that does not fully adapt with prolonged GLP-1 agonism. This is why:

• Nausea is front-loaded at each dose step and typically improves within 2–4 weeks
• Constipation can persist or worsen with dose escalation and may remain at maintenance dose

Trial data supports this: constipation rates are higher at higher doses in both semaglutide and tirzepatide trials, and persistence beyond the initial adaptation period is documented.

The hydration factor

Dehydration worsens constipation in a cycle that GLP-1 therapy particularly enables. When appetite is suppressed, patients eat and drink less — including less fluid. Less total fluid intake means less colonic fluid content, harder stools, and more difficult transit.

Many GLP-1 patients significantly under-hydrate without realising it. The sensation of thirst does not always signal dehydration clearly in states of appetite suppression.

Target: At least 2 litres (8 glasses) of fluid daily — water, unsweetened beverages, soups. Caffeinated drinks have mild diuretic effect; they count toward fluid intake but are not the primary source.

Practical reinforcement: Setting a reminder or using a measured container helps patients who are not naturally thirsty on GLP-1 therapy.

Dietary strategies

Dietary fibre increases stool bulk and stimulates colonic peristalsis. Increasing fibre intake is one of the most consistently effective constipation interventions.

Practical sources:

• Vegetables (particularly leafy greens, broccoli, legumes)
• Fruit with skin intact (apples, pears, berries)
• Whole grains (oats, wholemeal bread, brown rice)
• Legumes (lentils, chickpeas, beans)

Increase gradually: Sudden large increases in fibre intake can cause bloating and gas. Increase fibre slowly over 1–2 weeks.

Note: Some patients on GLP-1 therapy already have difficulty eating adequate volumes due to appetite suppression. If low caloric intake is severely restricting fibre intake, this may require specific dietary planning with a registered dietitian.

Physical activity

Movement stimulates colonic motility. Patients who are sedentary have slower colonic transit than those who are physically active. Even moderate exercise — walking 30 minutes daily — has consistent evidence for improving constipation.

GLP-1 therapy's early side effects (fatigue, nausea) sometimes reduce activity levels. Maintaining at least light activity during treatment helps prevent constipation worsening.

Laxatives: which ones are appropriate

Osmotic laxatives (first-line for ongoing use):

• Polyethylene glycol (MiraLAX, Movicol): draws water into the colon, softening stool. Safe for ongoing use. Generally appropriate alongside GLP-1 therapy.
• Lactulose: similar mechanism. May cause gas and bloating in some patients.
• Magnesium hydroxide (Milk of Magnesia): osmotic effect, faster acting than PEG.

Stimulant laxatives (short-term use):

• Senna, bisacodyl: stimulate colonic muscle contractions. Effective but not intended for chronic daily use. Appropriate for episodic constipation breakthrough.

Stool softeners:

• Docusate sodium: draws water into the stool. Limited standalone evidence but widely used and generally safe.

Fibre supplements:

• Psyllium (Metamucil), methylcellulose: bulking agents. Work best with adequate fluid intake — take with a full glass of water.

Discuss laxative choice with your prescriber — some patients have contraindications or comorbidities affecting which options are appropriate.

When to contact your prescriber

Contact your prescriber or seek evaluation for:

• No bowel movement for more than 5–7 days despite appropriate management
• Severe abdominal pain accompanying constipation
• Significant abdominal distension
• Vomiting accompanying constipation (raises concern for obstruction)
• Blood in stool (separate from constipation-related anal fissures, which produce small amounts of bright red blood)

Routine constipation — infrequent bowel movements but manageable with dietary changes and occasional laxatives — does not typically require urgent evaluation.

Editorial note: This article awaits medical-reviewer signoff. Constipation management should be discussed with your prescriber, particularly for patients with prior bowel conditions, on medications affecting gut motility, or with constipation that is severe or unresponsive to first-line measures.